DOI:
10.1055/s-00032260
Digestive Disease Interventions
LinksClose Window
References
Segal NH, Kemeny NE, Cercek A. et al.
Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients.
J Clin Oncol 2016;
34: 3539 .
https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.3539
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.